Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Quentin30 is a pathological prevaricator.

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Sep 17, 2024 9:28pm

97 Views

Post# 36228282

RE:RE:RE:RE:RE:RE:Quentin30 is a pathological prevaricator.

You seem to like putting people down. Hope that makes u feel better.
As for AA , yes onc will go for it in the upcoming trial as they stated in the presentation but they did not mention after mbc os.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"